The amount of patient recruitment milestone payments under collaboration arrangement.

No definition available.

Name:	nvct_CollaborativeArrangementPatientRecruitmentMilestonePayments
Namespace Prefix:	nvct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of pre approval milestone payments under collaboration arrangement.

+ References

No definition available.

+ Details

Name:	nvct_CollaborativeArrangementPreApprovalMilestonePayments
Namespace Prefix:	nvct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of regulatory approval and commercial sales milestone payments under collaboration arrangement.

+ References

No definition available.

+ Details

Name:	nvct_CollaborativeArrangementRegulatoryApprovalAndCommercialSalesMilestonePayments
Namespace Prefix:	nvct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The royalty payments as percent of sales under collaboration agreement.

+ References

No definition available.

+ Details

Name:	nvct_CollaborativeArrangementRoyaltyPaymentsAsPercentOfSales
Namespace Prefix:	nvct_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of upfront payments under collaboration arrangement.

+ References

No definition available.

+ Details

Name:	nvct_CollaborativeArrangementUpfrontPayments
Namespace Prefix:	nvct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of license fees related to research and development.

+ References

No definition available.

+ Details

Name:	nvct_LicenseFees
Namespace Prefix:	nvct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of project cost expensed during the period.

+ References

No definition available.

+ Details

Name:	nvct_ProjectCost
Namespace Prefix:	nvct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=nvct_CrtPioneerFundLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COMMITMENTS AND CONTINGENCIES - CRT Pioneer Fund License Agreement (Details) - USD ($)		1 Months Ended	12 Months Ended
	Mar. 31, 2022	May 31, 2021	Dec. 31, 2025	Dec. 31, 2024
COMMITMENTS AND CONTINGENCIES
Research and development			$ 18,153,000	$ 12,918,000
License fees			2,438,000	5,000
CRT Pioneer Fund License Agreement
COMMITMENTS AND CONTINGENCIES
Non refundable payment		$ 3,500,000
Patient recruitment milestones		$ 1,000,000
Royalties		10.00%
Research and development	$ 865,000
Project cost			0	0
License fees			$ 0	$ 0
CRT Pioneer Fund License Agreement \| Maximum
COMMITMENTS AND CONTINGENCIES
Pre - approval milestone		$ 26,500,000
Commercial sales milestone		$ 178,000,000